<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03046238</url>
  </required_header>
  <id_info>
    <org_study_id>222</org_study_id>
    <nct_id>NCT03046238</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Breast Cancer Patients</brief_title>
  <official_title>Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Patient Undergoing Breast Cancer Surgery :A Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Egypt Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Egypt Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate the effect of addition of Dexmedetomedine to ultrasound guided modified Pecs
      block on post operative analgesia &amp; stress response in patient undergoing modified radical
      mastectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 patients (age ≥29 years) who scheduled for modified radical mastectomy surgery under
      general anesthesia. Group I (Bupivacaine group): patients underwent modified radical
      mastectomy were given preoperative ultrasound guided modified Pecs block with 30 mL of 0.25%
      bupivacaine divided into 10 ml injected between the pectoralis muscles on the interfasial
      plane, and 20 ml injected between the Pectoralis minor muscle and the serratus muscle.Group
      II (Bupivacaine + Dexmedetomidine group) : preoperative ultrasound guided modified Pecs block
      with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg) divided into 20 ml injected
      between the pectoralis muscles on the interfasial plane , and 10 ml injected between the
      Pectoralis minor muscle and the serratus muscle.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2017</start_date>
  <completion_date type="Anticipated">April 2, 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>morphine consumption mg/day</measure>
    <time_frame>48 HOURS</time_frame>
    <description>by Patient-controlled analgesia (PCA) device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS), scored from 0-10</measure>
    <time_frame>48 hours</time_frame>
    <description>pain measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>first request of analgesia</measure>
    <time_frame>48 hours</time_frame>
    <description>time of the first request of analgesia postoperative if the VAS ≥ 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of stress hormones</measure>
    <time_frame>48 hours</time_frame>
    <description>cortisol level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>48 hours</time_frame>
    <description>Nausea Vomiting Bradycardia Hypotension Arrhythmia Pneumothorax Vascular injury Nausea Vomiting Bradycardia Hypotension Arrhythmia Pneumothorax Vascular injury Nausea,Vomiting,Arrhythmia.Hypotension,Pneumothorax,Vascular injury andItching</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer Patients</condition>
  <arm_group>
    <arm_group_label>dexmetedomedine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)</description>
    <arm_group_label>dexmetedomedine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine</description>
    <arm_group_label>control</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I - II patients

          -  weight 50- 100 kg)

        Exclusion Criteria:

          -  a history of bleeding diathesis,

          -  relevant drug allergy

          -  opioid dependence,

          -  sepsis,

          -  those with psychiatric illnesses
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mohamad F mohamad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saher mohamad, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cancer Institute, Anesthesia, Intensive Care, and Pain Management, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>mohamad F mohamad, MD</last_name>
    <phone>+201093942354</phone>
    <email>mfaroukma@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>South Egypt Cancer Institute, Assiut University, Assiut, Egypt.</name>
      <address>
        <city>Assuit</city>
        <zip>171516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>February 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Egypt Cancer Institute</investigator_affiliation>
    <investigator_full_name>Dr.mohamad farouk mohamad</investigator_full_name>
    <investigator_title>lecturer of anesthesia,ICU and pain relief</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

